FDA approves a medicine to help prevent bone complications in adults whose cancer has spread to bone
Teva Pharmaceutical Industries (TEVA) received FDA approval for DEGEVMA, a biosimilar to Xgeva, for preventing bone complications in cancer patients and treating giant cell tumor of bone. This is Teva's second FDA-approved biosimilar in 2026, following PONLIMSI's approval in March. The company anticipates launching both products in the U.S. soon. DEGEVMA is also approved in the EU and will be supplied as a 120mg/1.7mL injection vial.
How this was made
The 30-second read
Why it matters
The approval enables U.S. commercialization, likely adding incremental sales and improving Teva's growth outlook.
Market read
First FDA clearance for this biosimilar; traders may position ahead of launch.
What to watch
Potential reimbursement challenges and competition from other biosimilars.
Background
Teva announced FDA approval for DEGEVMA, a denosumab biosimilar to Amgen's Xgeva, expanding its oncology biosimilar portfolio.
Ticker impact
FDA approval of DEGEVMA biosimilar expands Teva's oncology portfolio and enables U.S. launch.
upward pressure as investors price in new product revenue.
First-time FDA clearance for a denosumab biosimilar; market typically reacts positively to such approvals.
Market effects
Strengthens the biosimilar segment within pharma, may pressure branded denosumab competitors.
Positive for U.S. biotech stocks, especially those with FDA pipelines.
Highlights growing biosimilar adoption worldwide.
Counterpoint
If pricing is too low, margins could be squeezed, limiting upside.
Key entities
- companyTeva Pharmaceutical Industries
US-listed pharmaceutical company receiving FDA approval.
- companyAmgen Inc.
Holder of the reference product Xgeva.
